Identification of new prognostic biomarkers in chronic heart failure: Prospective longitudinal observational cohort study of patients with chronic heart failure and with or without diabetes mellitus

Identification of new prognostic biomarkers in chronic heart failure: Prospective longitudinal observational cohort study of patients with chronic heart failure and with or without diabetes mellitus - Aachen Longitudinal Heart Failure and Diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025557

Enrollment

4000

Registered

2021-11-08

Start date

2019-05-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50 E11

Interventions

Group 1: Observation group: patients with chronic heart failure (with or without diabetes)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Older than 18 years old 2. Written declaration of consent 3. Persons who are legally competent and mentally able to follow the instructions of the study staff. 4. Chronic heart failure: Symptoms compatible with heart failure with age-dependent and guideline-based elevated NT-proBNP levels and echocardiographic criteria of heart failure and stable clinical course for at least 4 weeks.

Exclusion criteria

Exclusion criteria: 1. Younger than 18 years 2. Pregnant and breastfeeding women (will be asked) 3. Primary valve vitia 4. acute myocarditis 5. Alcohol abuse 6th line after Chemotherapy or radiation therapy (thoracic area) 7. primary cardiomyopathies (except dilated forms) 8. Tachycardia-related and so-called Tako-Tsubo cardiomyopathies 9. with congenital heart defects (GUCH) 10. Type 1 diabetes 11. CDK Stage 5d 12. COPD with chronic home oxygen needs 13. Immobility with dependency

Design outcomes

Primary

Measure	Time frame
cardiovascular mortality	—

Secondary

Measure	Time frame
• Hospitalization (first and recurring) due to heart failure • Hospitalization (first and recurring) due to any cause • Hospitalization due to fatal and non-fatal pulmonary embolism • Hospitalization due to severe bacterial or viral infection • Time until sepsis occurs • Length of time to non-cardiac death • Time to total mortality • Time to non-fatal heart attack • Time to non-fatal acute coronary syndrome • Time to survived sudden cardiac death • Time to non-fatal end stage renal failure • How long it takes to develop non-steroidal diabetes in patients with prediabetes • Time taken to develop nonsteroidal diabetes in patients with normoglycemia • Time taken to develop non-steroidal prediabetes in patients with normoglycemia • Time taken to develop HFrEF in patients with HFmrEF • Time taken to develop HFrEF in patients with HFpEF • Time taken to develop HFmrEF in patients with HFpEF	—

Measure

Time frame

• Hospitalization (first and recurring) due to heart failure • Hospitalization (first and recurring) due to any cause • Hospitalization due to fatal and non-fatal pulmonary embolism • Hospitalization due to severe bacterial or viral infection • Time until sepsis occurs • Length of time to non-cardiac death • Time to total mortality • Time to non-fatal heart attack • Time to non-fatal acute coronary syndrome • Time to survived sudden cardiac death • Time to non-fatal end stage renal failure • How long it takes to develop non-steroidal diabetes in patients with prediabetes • Time taken to develop nonsteroidal diabetes in patients with normoglycemia • Time taken to develop non-steroidal prediabetes in patients with normoglycemia • Time taken to develop HFrEF in patients with HFmrEF • Time taken to develop HFrEF in patients with HFpEF • Time taken to develop HFmrEF in patients with HFpEF

—

Countries

Germany

Contacts

Public ContactMarlo Verket

Med. Klinik I, Uniklinikum RWTH Aachen

mverket@ukaachen.de+492418038067

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026